Thyroid cancer has many different types that affect hundreds of thousands of people world-wide. There hasn’t been a “cure” found, per-say, but science has been moving closer and closer in that direction.
Recently, the U.S. Food and Drug Administration approved a treatment for a rare type of thyroid cancer called metastic medullary thyroid cancer, or MTC.
MTC is abnormal in that “unlike 90 percent of differentiated thyroid cancers, MTC does not respond to the most common treatments, making it difficult to manage.” Not to mention that it usually isn’t detected until it’s at a late stage.
However, the new drug called cabozantinib, “blocks the gene” that causes MTC. It’s an extraordinary discovery that will begin to help patients immediately.
Some side effects have been noted to include vomiting, diarrhea, stomach pains, weight loss, and constipation. Lower the dosage of the drug helps reduce these symptoms if any of them appear.
Cabozantinib may not be the cure for cancer, but it is definitely one step in the right direction. Researchers are now looking into using it as “a therapy for numerous tumor types, including prostate, ovarian, brain, melanoma, breast, and non-small cell lung cancers.”
With this innovation, I can’t wait to see what the future holds for those who suffer the ultimate diagnosis.
Want more info? Click here.